Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0120


Breast cancer: Trastuzumab for HER2-positive patients and molecular systems approach.

George Zografos, M.D.

Affiliation: Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens , Greece .

Tel: +306932524836




Advances in science and sequencing technologies together with observation of long-term follow-up studies provide now an in-depth analysis of genetic bases of cancer. Two studies from famous, highly specialized institutions, report that despite an overall good prognosis, some patients with very early breast cancer are presented with an aggressive phenotype, high recurrence and fatal outcome.

In this article, it is discussed whether these high-risk women are those with HER2-overexpressing tumors who might benefit from systemic treatment with the monoclonal antibody trastuzumab. Limitations of these studies and molecular systems approaches-based research directions are also discussed.





You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 6 March 2010